EXACT Sciences — Q1 2023 Earnings Presentation
16 slides from EXACT Sciences's earnings presentation, May 9, 2023
Slide 1: First quarter 2023 earnings call
We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. First quarter 2023 earnings call May 9, 2023 EXACT SCIENCES 1
Slide 2: Safe harbor and non-GAAP disclosures
Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub
Slide 3: Delivering innovative tests that help prevent cancer, detect it earlier, and guide treatment
Delivering innovative tests that help prevent cancer, detect it earlier, and guide treatment to patients globally OUR TEAM OUR FLAGSHIP TESTS RECORD Q1 RESULTS 500 1M+ Record total revenue of $602M, 33% core revenue growth R&D team members people tested in 1Q23 1,200 Raising 2023 guidance for revenu
Slide 4: Core revenue grew 33% in 1Q23
Core revenue grew 33% in 1Q23 Core revenue Screening revenue Precision Oncology revenue $598M Precision Oncology Oncotype DX Prostate test +33% $443M $450M +45% $307M $153M $155M +2% $153M $144M 1Q22 1Q23 1Q22 1Q23 1Q22 1Q23 Core revenue excludes COVID testing revenue, the divested Oncotype DX prost
Slide 5: Updated 2023 guidance
Updated 2023 guidance Prior guidance May 9 update ∆ at midpoint Total revenue $2.265 - 2.315B $2.380 - 2.420B +$110M Screening $1.660 - 1.690B $1.770 - 1.795B +$108M Precision Oncology $600 - 620M $605 - 620M +$3M COVID testing ~$5M ~$5M - Adj. EBITDA $0 - 25M $100 - 125M +$100M CapEx ~$120M ~$120M
Slide 6: Cologuard can help screen million unscreened Americans
Cologuard can help screen 60 million unscreened Americans accurately, easily, and in the privacy of their home 60M 10 years unscreened Americans to screen everyone due today ages 45 to 85 with colonoscopy alone Source: Fisher D et al., ASCO Gastrointestinal Cancers Symposium abstract (2022); Exact S
Slide 7: Health systems are increasingly relying on Cologuard to close the colorectal cancer screening gap
Health systems are increasingly relying on Cologuard to close the colorectal cancer screening gap 300 Cumulative electronic ordering interfaces with health systems 275+ 250 50% 200 150 higher market share in largest 400 systems vs. independent practices 100 and smaller systems 50 0 2015 2016 2017 20
Slide 8: Guiding treatment decisions for more than 200,000 cancer patients every year
Guiding treatment decisions for more than 200,000 cancer patients every year Test reach Unmatched evidence 1.8M+ 500+ Durable revenue High margins cumulative publications patients tested and abstracts Steady cash flow Source: Exact Sciences internal data EXACT SCIENCES 8
Slide 9: Advancing our pipeline of life-changing diagnostics
Advancing our pipeline of life-changing diagnostics Colorectal cancer screening (CRC) Milestones in 2023 110M people in U.S. Top-line next-generation Cologuard BLUE-C data Multi-cancer early detection (MCED) 135M people in U.S. Two studies further validating multi-marker class approach Molecular res
Slide 10: We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment
We aim to eradicate cancer with tests that help prevent it, detect it earlier, and guide treatment. EXACT SCIENCES 10
Slide 11: EXACT SCIENCES
EXACT SCIENCES 11
Slide 12: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended March 31, 2023 2022 Revenue $ 602,450 $ 486,571 Operating expenses Cost of sales (exclusive of amortization of acquired
Slide 13: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) March 31, 2023 December 31, 2022 Assets Cash and cash equivalents $ 421,365 $ 242,493 Marketable securities 277,282 389,564 Accounts receivable, net 183,371 158,043 Invent
Slide 14: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended March 31, (In thousands) 2023 2022 Net loss $ (74,151) $ (180,937) Interest expense (income) (1) (4,107) 4,478 Depreciation and amortization 49,743
Slide 15: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended March 31, 2023 2022 Revenue $ 602,450 $ 486,571 Cost of sales (exclusive of amortization of acquired intangible assets) 156,86
Slide 16: Selected Unaudited Financial Information
EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended March 31, 2023 2022 % Change Screening $ 443,195 $ 306,522 45 % Precision Oncology 155,432 152,620 2% COVID-19 Testing 3,823 27,429 (86)% Total $ 602,450